Add news
News Every Day |

First new treatment for asthma and COPD in half a century – new study

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these potentially life-threatening episodes has remained unchanged – treatment with steroids, such as prednisolone.

Unfortunately, these drugs don’t work for everyone and they have significant levels of serious side-effects. Nearly one-third of patients treated with steroids will see their symptoms worsen again within a month, requiring more treatment and increasing the risk of side-effects.

But what if there was a better option?

Our latest study, published in The Lancet Respiratory Medicine, has revealed that a drug called benralizumab – administered as an injection – may be the breakthrough that we have been waiting for. The results suggest that this treatment, administered at the time of a flare-up, is highly effective and spares patients the side-effects of steroids.

Inflammation caused by a type of white blood cell called eosinophils is a key driver of flare-ups in many people with asthma and some people with COPD. Eosinophilic inflammation plays a role in at least half of asthma and one-third of COPD flare-ups. For these people, targeting eosinophils when symptoms worsen is a promising strategy.

Benralizumab, a monoclonal antibody, is already used for the long-term management of eosinophilic asthma, with studies still evaluating the effect for long-term management in eosinophilic COPD. However, the potential to manage critical moments, when symptoms suddenly worsen, had not been studied before.

In the trial, 158 patients experiencing asthma or COPD flare-ups were recruited from two UK hospitals. Participants were randomly assigned to one of three groups: standard treatment with prednisolone tablets, a single injection of benralizumab alone, or a combination of the two.

Corticosteroids come with a lot of side-effects, including some serious ones. Sonis Photography/Shutterstock

Striking results

The main outcome we were interested in was the “rate of treatment failure”, defined as the need for further therapy, hospitalisation or death, within 90 days.

The results were striking: 74% of those treated with prednisolone alone experienced treatment failure within 90 days. Failure rates dropped to 47% with benralizumab alone and 42% with the combination therapy.

Pooled data from the benralizumab-treated groups showed that only 45% of patients experienced treatment failure, compared with 74% in the prednisolone group. For every four patients treated with benralizumab, one treatment failure was prevented.

The benefits of benralizumab extended beyond treatment failure rates. Patients treated with benralizumab reported faster symptom recovery and improved quality of life. For example, patients were able to breathe better and had less discomfort.

Benralizumab also had a better safety profile compared with prednisolone. Side-effects commonly linked to prednisolone, such as high blood sugar, were absent in patients who received benralizumab alone.

This makes the therapy especially promising for people who face significant risks from repeated prednisolone use, such as older adults and those with diabetes or osteoporosis.

While a lower dose of benralizumab is already approved for long-term asthma management, it is not yet licensed for use during flare-ups at the dose used in this study. For that to happen, phase 3 trials will be needed, involving more diverse and international populations. (Phase 3 is the final phase of testing in humans before a drug is approved.)

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations of asthma and COPD in over 50 years.

In the time it has taken you to read this article, 40 people in the world have experienced an eosinophilic asthma or COPD flare-up. Under current best treatments, 30 of them will require further care within 90 days. Benralizumab offers the potential to break this cycle of recurrent treatment and side-effects, transforming the way we manage these common and debilitating conditions.

Could this drug be the breakthrough we’ve been waiting for? The early evidence suggests it just might be.

Mona Bafadhel receives funding from the National Institute of Health Research, Asthma+Lung UK, and Horizon Europe. For this study, Mona Bafadhel received funding from AstraZeneca to complete the study described in this report. The funder (AstraZeneca) was not involved in the study design, data collection, data analysis, data interpretation or decision to submit to publish.

Richard Russell has received personal grants for Consultations with AstraZeneca Ltd.

Sanjay Ramakrishnan receives funding from the National Institute for Health and Care Research (NIHR) and The Charlie's Research Foundation. Sanjay Ramakrishnan's institution received funding from AstraZeneca to conduct the study reported in the article.

Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine

Darts star leaks World Championship payslip as he reveals long list of ‘deductions’ left him with just £5,200 winnings

Creating and sharing deepfakes through tools such as OpenAI is now a crime in New Jersey—punishable by up to 5 years in prison

Here’s more of what you’ll see through Meta’s $1,000 smart glasses

The Ashton Jeanty Bears Smoke Just Got Even Thicker

Ria.city
Реклама
  • ИП Попов А.П.
  • ИНН: 602715631406
Ревматолог: "5 апреля 2024 в г.Вашингтон запущена квота"

Каждый человек с больными суставами имеет право получить...






Реклама
  • ИП Попов А.П.
  • ИНН: 602715631406
Ревматолог: "5 апреля 2024 в г.Вашингтон запущена квота"

Каждый человек с больными суставами имеет право получить...


Реклама
  • ИП Попов А.П.
  • ИНН: 602715631406
Ревматолог: "5 апреля 2024 в г.Вашингтон запущена квота"

Каждый человек с больными суставами имеет право получить...

Read also

Can Kim Soo-hyun work his way back to the spotlight?

APC mourns Ogun publicity secretary, Oladunjoye

I retired at 41 to spend time with my grandkids. I supplemented my income with part-time work.

News, articles, comments, with a minute-by-minute update, now on Today24.pro

News Every Day

Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market

Today24.pro — latest news 24/7. You can add your news instantly now — here


News Every Day

Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market



Sports today


Новости тенниса
Дарья Касаткина

Теннисистка Касаткина потерпела первое поражение под флагом Австралии



Спорт в России и мире
Москва

Школьница из Ноябрьска отправится на стажировку в Китай



All sports news today





Sports in Russia today

Москва

Детский турнир по водному поло впервые состоится в Кисловодске


Новости России

Game News

It's actually happening, everybody stay calm: Silksong properly confirmed for a 2025 release date at the Nintendo Direct with a whole 3 seconds of footage


Реклама
Top 6 nutrition questions men should ask themselves after 40

To maintain health and remain full of energy, men will be helped by this

Реклама
Top 6 nutrition questions men should ask themselves after 40

To maintain health and remain full of energy, men will be helped by this

Реклама
Top 6 nutrition questions men should ask themselves after 40

To maintain health and remain full of energy, men will be helped by this

Russian.city

Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine


Москва

Школьница из Ноябрьска отправится на стажировку в Китай


Губернаторы России
Регина Тодоренко

Тодоренко вновь проиграла иск против петербургской писательницы


На Москву надвигается непогода: может выпасть до 15 см снега

Когда слово объединяет: ГПМ Радио приглашает на «Тотальный диктант»

Заказать Напосим 10 Воркута

Московский Экономический Форум: главное


Юань — наше «завтра» // Объем биржевых торгов китайской валютой стабильно превышает 100 млрд рублей в день

Кураторские Плейлисты.

VK Fest 2025: Баста, L'One и BLIZKEY рассказали что происходит за кулисами фестиваля

При падении машины с пятого этажа парковки в Москве погибла педагог Гнесинки


Марракеш (ATP). 1/4 финала. Карбаллес Баэна сыграет с Боржесом, Грикспор встретится с Беллуччи

Екатерина Александрова уверенно обыграла Диану Шнайдер в 3-м круге турнира в Чарльстоне

Александрова вышла в полуфинал турнира WTA в Чарльстоне

Медведев пошутил, что теннис является странным видом спорта


Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine


Кинотеатр в метро и ТЦ под землей: какие футуристические здания могли появиться в Москве

В Москве был ранен открывший стрельбу по полицейским правонарушитель

Мужчина в Москве открыл стрельбу по полицейским, его ранили ответным огнем

"Коммерсантъ": экс-губернатор Куйвашев стал фигурантом коррупционного дела


Сергей Собянин: Оплата проезда по биометрии появится на всех станциях МЦД

Рейтинг пяти лучших маркетинговых агентств: VICTORY GROUP занял первое место

Никоненко заявил об отказе играть с Михаилом Ефремовым, выходящим по УДО

Набирать текст в Google Messages станет приятнее — снимут ограничения


Суд Москвы арестовал главу управления Госстройнадзора Минобороны по делу о взятках

Елизавета Боярская шокировала откровенной сценой в новом сериале

Лесной пожар потушили вблизи деревни Островцы

Виолончелист Александр Рамм покоряет Карелию


Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine


Путин в России и мире
Реклама
Top 6 nutrition questions men should ask themselves after 40

To maintain health and remain full of energy, men will be helped by this



Реклама
Top 6 nutrition questions men should ask themselves after 40

To maintain health and remain full of energy, men will be helped by this



Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine



Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine

Персональные новости Russian.city
Александр Розенбаум

Александр Розенбаум зарегистрирует фразы из своих песен как товарные знаки



News Every Day

Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market




Friends of Today24

Музыкальные новости

Персональные новости